SCOPOLAMINE Drug Patent Profile
✉ Email this page to a colleague
When do Scopolamine patents expire, and when can generic versions of Scopolamine launch?
Scopolamine is a drug marketed by Actavis Labs Ut Inc, Mylan Technologies, Padagis Us, and Riconpharma Llc. and is included in four NDAs.
The generic ingredient in SCOPOLAMINE is scopolamine. There are twenty-one drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the scopolamine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Scopolamine
A generic version of SCOPOLAMINE was approved as scopolamine by PADAGIS US on January 30th, 2015.
Summary for SCOPOLAMINE
US Patents: | 0 |
Applicants: | 4 |
NDAs: | 4 |
Finished Product Suppliers / Packagers: | 6 |
Raw Ingredient (Bulk) Api Vendors: | 41 |
Clinical Trials: | 79 |
Patent Applications: | 3,848 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for SCOPOLAMINE |
DailyMed Link: | SCOPOLAMINE at DailyMed |
Recent Clinical Trials for SCOPOLAMINE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Dartmouth-Hitchcock Medical Center | Phase 1 |
EMS | Phase 2 |
Assiut University | Phase 4 |
Pharmacology for SCOPOLAMINE
Drug Class | Anticholinergic |
Mechanism of Action | Cholinergic Antagonists |
Anatomical Therapeutic Chemical (ATC) Classes for SCOPOLAMINE
US Patents and Regulatory Information for SCOPOLAMINE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Actavis Labs Ut Inc | SCOPOLAMINE | scopolamine | SYSTEM;TRANSDERMAL | 208769-001 | Jan 10, 2022 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Riconpharma Llc | SCOPOLAMINE | scopolamine | SYSTEM;TRANSDERMAL | 212342-001 | Nov 24, 2020 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Mylan Technologies | SCOPOLAMINE | scopolamine | SYSTEM;TRANSDERMAL | 203753-001 | Jun 19, 2019 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Padagis Us | SCOPOLAMINE | scopolamine | SYSTEM;TRANSDERMAL | 078830-001 | Jan 30, 2015 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |